{"title":"经皮冠状动脉介入治疗需要口服抗凝剂的患者，双重抗血栓治疗支架血栓形成的风险:随机试验荟萃分析的见解","authors":"Toshiki Kuno, Hiroki Ueyama, Hisato Takagi, Sripal Bangalore","doi":"10.1080/14017431.2021.2025264","DOIUrl":null,"url":null,"abstract":"<p><p>Recent meta-analyses investigating dual antithrombotic therapy (DAT) versus triple antithrombotic therapy (TAT) among patients who require oral anticoagulants especially with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) raised the concern of stent thrombosis (ST) and myocardial infarction (MI), however, these meta-analyses did not include all randomized trials who require oral anticoagulants. We aimed to investigate the efficacy of DAT versus TAT in these patients undergoing PCI. Our data showed the risk of ST was not significantly different in DAT vs. TAT (HR [95%CI]: 1.50 [0.97-2.34], <i>p</i> = .07; <i>I</i><sup>2</sup> = 0%) and MI (HR [95%CI]: 1.17 [0.95-1.45], <i>p</i> = .14; <i>I</i><sup>2</sup> = 0%).</p>","PeriodicalId":137876,"journal":{"name":"Scandinavian cardiovascular journal : SCJ","volume":" ","pages":"1-3"},"PeriodicalIF":0.0000,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The risk of stent thrombosis of dual antithrombotic therapy for patients who require oral anticoagulant undergoing percutaneous coronary intervention: insights of a meta-analysis of randomized trials.\",\"authors\":\"Toshiki Kuno, Hiroki Ueyama, Hisato Takagi, Sripal Bangalore\",\"doi\":\"10.1080/14017431.2021.2025264\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Recent meta-analyses investigating dual antithrombotic therapy (DAT) versus triple antithrombotic therapy (TAT) among patients who require oral anticoagulants especially with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) raised the concern of stent thrombosis (ST) and myocardial infarction (MI), however, these meta-analyses did not include all randomized trials who require oral anticoagulants. We aimed to investigate the efficacy of DAT versus TAT in these patients undergoing PCI. Our data showed the risk of ST was not significantly different in DAT vs. TAT (HR [95%CI]: 1.50 [0.97-2.34], <i>p</i> = .07; <i>I</i><sup>2</sup> = 0%) and MI (HR [95%CI]: 1.17 [0.95-1.45], <i>p</i> = .14; <i>I</i><sup>2</sup> = 0%).</p>\",\"PeriodicalId\":137876,\"journal\":{\"name\":\"Scandinavian cardiovascular journal : SCJ\",\"volume\":\" \",\"pages\":\"1-3\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Scandinavian cardiovascular journal : SCJ\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14017431.2021.2025264\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian cardiovascular journal : SCJ","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14017431.2021.2025264","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/8 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
The risk of stent thrombosis of dual antithrombotic therapy for patients who require oral anticoagulant undergoing percutaneous coronary intervention: insights of a meta-analysis of randomized trials.
Recent meta-analyses investigating dual antithrombotic therapy (DAT) versus triple antithrombotic therapy (TAT) among patients who require oral anticoagulants especially with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) raised the concern of stent thrombosis (ST) and myocardial infarction (MI), however, these meta-analyses did not include all randomized trials who require oral anticoagulants. We aimed to investigate the efficacy of DAT versus TAT in these patients undergoing PCI. Our data showed the risk of ST was not significantly different in DAT vs. TAT (HR [95%CI]: 1.50 [0.97-2.34], p = .07; I2 = 0%) and MI (HR [95%CI]: 1.17 [0.95-1.45], p = .14; I2 = 0%).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
